Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A realworld study

被引：0
|
作者：
Yang, Xiaojian [1 ]
Quan, Penghe [1 ]
Yu, Changjiang [1 ]
机构：
[1] Air Force Mil Med Univ, XIjing Hosp, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16592
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 Study
    Kang, Ok-Ju
    Cho, Yoon-Jung
    Lim, Myong Cheol
    Lee, Yeon Jee
    Seo, Sang Soo
    Kang, Sokbom
    Park, Sang-Yoon
    Kim, Young Seok
    Nam, Joo-Hyun
    Park, Jeong-Yeol
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (05): : 1229 - 1236
  • [42] The efficacy and safety study of thymosin a1 combined with PD-1 antibodies as adjuvant therapy in patients with hepatocellular carcinoma with high-risk recurrence factors after radical resection
    Zhu RongHua
    Huang Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UPFROMTHE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
    Galsky, Matthew
    Witjes, Johannes Alfred
    Gschwend, Jurgen E.
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh F.
    Park, Se Hoon
    Agerbaek, Mads
    Jha, Gautam
    Stenner, Frank Stenner
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Nasroulah, Federico
    Zhang, Joshua
    Bajorin, Dean F.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E183 - E183
  • [44] Preliminary results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence.
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] First-line Treatment for locally advanced or metastatic Urothelial Carcinoma: A randomized, double-blind Phase-III-Multicenter Study of adjuvant Nivolumab Therapy versus Placebo in Patients with invasive High-Risk Urothelial Carcinoma
    Rexer, H.
    Ohlmann, C. -H.
    Gschwend, J.
    AKTUELLE UROLOGIE, 2018, 49 (04) : 308 - 309
  • [46] Gene expression as a predictive marker of outcome for high risk transitional-cell carcinoma (TCC) of the bladder in patients (PTS) randomized to adjuvant chemotherapy with cisplatin-gemcitabine (PG) or observation (OBS) after radical cystectomy
    Pollera, C. F.
    Pessina, G.
    Nelli, F.
    Felici, A.
    Sperduti, I
    Ruggeri, E. M.
    Mottolese, M.
    Gallucci, M.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [47] Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 571 - 571
  • [48] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery-A single-arm, multicenter, phase II clinical trial.
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16120 - E16120
  • [49] HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: A single-centre, non-randomised, open clinical study
    Zhang, T.
    Wang, L.
    Zhao, Y.
    Pan, Q.
    Mao, A.
    Zhu, W.
    Zhang, N.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S597 - S597
  • [50] Gene expression as a predictive marker of outcome for high-risk transitional-cell carcinoma (TCC) of the bladder in patients (pts) randomized to adjuvant chemotherapy with cisplatin-gemcitabine (PG) or observation (OBS) after radical cystectomy
    Pollera, C. F.
    Pessina, G.
    Nelli, F.
    Felici, A.
    Moscetti, L.
    Ruggeri, E.
    Mottolese, M.
    Gallucci, M.
    Sperduti, I.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345